Emily Bodnar
Recent Articles about BriaCell Therapeutics Corp.
Co.'s Breast Cancer Therapy Shows Encouraging Activity 12/28/2023
BriaCell Therapeutics Corp.'s lead targeted cell therapy, when combined with the PD-1 inhibitor retifanlimab, achieved an exceptional 71% intracranial objective response rate treating brain metastases in advanced breast cancer patients, according to an H.C. Wainwright report.
Biotech Announces New Responder in Breast Cancer Trail 11/30/2023
Recently, BriaCell Therapeutics Corp. announced a new exceptional responder in its Phase 2 study evaluating the company's off-the-shelf personalized immunotherapy, noted H.C. Wainwright analyst Emily Bodnar.
© 2024 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
